Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double‐blind, randomized, controlled trial

Abstract

EGF can significantly reduce healing time of skin lesions in patients with pemphigus vulgaris, at least when this cream base is applied (Cochrane skin group identifier: CSG20).

Therapy for Unhealed Gastrocutaneous Fistulas in Rats as a Model for Analogous Healing of Persistent Skin Wounds and Persistent Gastric Ulcers: Stable Gastric Pentadecapeptide BPC 157, Atropine, Ranitidine, and Omeprazole

“…The unmistakable attribution is important to avoid all of the dilemmas with standard peptides, despite the healing of the gastric ulcer (for illustration see, i.e., [6]) and skin wound extensively investigated (for illustration see, i.e., [27,[69][70][71][72][73]). Namely, standard peptides are unstable and require the addition of a carrier, particularly in wound healing [72,73] and peptide-carrier(s) complexes result in considerable methodological/activity dilemmas [72,73].…”

Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis

“…Topical EGF appears to hasten lesion healing according to one study in 20 patients [27]. However, it was not compared with the more commonly used therapy-topical corticosteroids-that may have yielded a similar response.…”

“…One trial compared the effect of topical EGF in a sulfadiazine base cream to sulfadiazine cream alone on the healing time of cutaneous lesions [27]. Time to healing was significantly shorter when EGF was used (HR 2.35, 95 % CI 1.62-3.41).…”

“…Baseline disease severity, which was assessed by different severity assessment tools, ranged from mild to severe; four trials did not report it [14,21,22,27] (Table 1).…”

“…The characteristics and main efficacy results of the 20 trials are displayed in Table 1 [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. The majority of studies included patients with newly diagnosed disease [8, 10-12, 14, 16, 18, 21] or a combination of newly diagnosed disease and recurrent disease [9,13,19,20,22,25,27]. Two studies included patients in the maintenance phase [23,24], one study included patients who had relatively resistant disease (had symptoms under treatment with prednisolone at C20 mg/day) [17].…”